| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
BMY
Bristol-Myers Squibb
|
Sep 10, 2026 | HOLD |
Buy
-1.3% avg upside
42 analysts
|
$65.00
4.12% Upside
|
-1.4% | Β· |
|
FR:SAN
Sanofi
|
Sep 10, 2026 | BUY |
Strong Buy
+33.8% avg upside
30 analysts
|
$100.00
37.73% Upside
|
-2.0% | Β· |
|
CH:ROP
Roche Holding AG
|
Sep 10, 2026 | HOLD |
Buy
-1.3% avg upside
24 analysts
|
$380.00
8.78% Upside
|
+4.7% | Β· |
|
GB:0QIU
Novo Nordisk
|
Sep 10, 2026 | HOLD |
Hold
+60.7% avg upside
29 analysts
|
$320.00
27.15% Upside
|
Β· | Β· |
|
DE:BAYN
Bayer
|
Sep 10, 2026 | BUY |
Buy
+15.4% avg upside
31 analysts
|
$65.00
36.26% Upside
|
+3.8% | Β· |
|
GB:GSK
GlaxoSmithKline
|
Sep 10, 2026 | HOLD |
Hold
+7.2% avg upside
26 analysts
|
$2000.00
9.10% Upside
|
+4.5% | Β· |
|
GB:AZN
AstraZeneca
|
Sep 10, 2026 | HOLD |
Strong Buy
+23.2% avg upside
28 analysts
|
$13920.00
13.29% Upside
|
+7.2% | Β· |
|
ABBV
AbbVie
|
Sep 10, 2026 | BUY |
Strong Buy
-6.9% avg upside
47 analysts
|
$315.00
20.41% Upside
|
+1.9% | Β· |
|
REGN
Regeneron
|
Sep 10, 2026 | BUY |
Strong Buy
+5.5% avg upside
59 analysts
|
$920.00
21.33% Upside
|
-0.7% | Β· |
|
PFE
Pfizer
|
Sep 10, 2026 | HOLD |
Buy
+17.8% avg upside
45 analysts
|
$30.00
5.21% Upside
|
+2.1% | Β· |
|
NVS
Novartis
|
Sep 10, 2026 | HOLD |
Buy
-2.1% avg upside
24 analysts
|
$136.00
4.62% Downside
|
+2.6% | Β· |
|
MRK
Merck & Company
|
Sep 10, 2026 | BUY |
Strong Buy
-1.9% avg upside
43 analysts
|
$172.00
18.35% Upside
|
-0.0% | Β· |
|
LLY
Eli Lilly & Co
|
Sep 10, 2026 | SELL |
Strong Buy
-6.8% avg upside
49 analysts
|
$940.00
18.85% Downside
|
-3.0% | Β· |
|
CH:NOVN
Novartis AG
|
Sep 09, 2026 | HOLD |
Buy
-6.2% avg upside
32 analysts
|
$110.00
8.32% Downside
|
+6.1% | Β· |
|
CH:LONN
Lonza Group Ltd
|
Jul 06, 2026 | BUY |
Strong Buy
+13.6% avg upside
21 analysts
|
$640.00
11.34% Upside
|
-0.9% | Β· |
|
CVS
CVS Health
|
Jul 06, 2026 | HOLD |
Strong Buy
+25.5% avg upside
39 analysts
|
$103.00
20.19% Upside
|
-15.5% | Β· |
|
FR:DIM
Sartorius Stedim Biotech
|
Jun 03, 2026 | BUY |
Strong Buy
+21.8% avg upside
12 analysts
|
$230.00
8.15% Upside
|
+15.6% | Β· |
|
RHHBY
Roche Holding
|
Dec 10, 2025 | BUY |
Buy
+0.8% avg upside
14 analysts
|
$57.00
9.82% Upside
|
+11.4% | Β· |
|
NVO
Novo Nordisk
|
Dec 10, 2025 | HOLD |
Hold
+206.0% avg upside
26 analysts
|
$54.00
42.37% Upside
|
-18.0% | Β· |
|
SNY
Sanofi
|
Dec 02, 2025 | BUY |
Strong Buy
+77.7% avg upside
20 analysts
|
$113.35
174.87% Upside
|
-12.7% | Β· |
|
ROG
Rogers
|
Dec 02, 2025 | BUY |
Strong Buy
+82.7% avg upside
6 analysts
|
$437.65
186.16% Upside
|
+60.5% | Β· |
|
GB:0NZT
UCB SA
|
Apr 28, 2025 | BUY |
Strong Buy
+7.7% avg upside
19 analysts
|
$179.00
13.41% Downside
|
+48.1% | Β· |
|
GB:0MGB
Genmab A/S
|
Apr 28, 2025 | BUY |
Strong Buy
-9.6% avg upside
25 analysts
|
$1990.00
14.17% Downside
|
+21.2% | Β· |
|
GILD
Gilead Sciences
|
Dec 04, 2024 | HOLD |
Strong Buy
-20.4% avg upside
66 analysts
|
$82.00
44.99% Downside
|
+37.9% | Β· |
|
IQV
IQVIA Holdings
|
Dec 04, 2024 | BUY |
Strong Buy
-7.1% avg upside
39 analysts
|
$270.00
0.34% Upside
|
+10.7% | Β· |
|
TMO
Thermo Fisher
|
Apr 30, 2024 | BUY |
Strong Buy
-8.8% avg upside
40 analysts
|
$670.00
0.72% Downside
|
-24.3% | Β· |
|
DHR
Danaher
|
Apr 16, 2024 | BUY |
Strong Buy
-3.0% avg upside
47 analysts
|
$280.00
26.33% Upside
|
-20.3% | Β· |
|
MRNA
Moderna
|
Feb 26, 2024 | SELL |
Hold
-45.7% avg upside
38 analysts
|
$86.00
55.38% Downside
|
+64.3% | Β· |
|
FERG
Ferguson Enterprises
|
Feb 14, 2024 | BUY |
Strong Buy
+70.0% avg upside
36 analysts
|
$233.73
5.05% Upside
|
-3.2% | Β· |
|
DE:MRK
Merck KGaA
|
Dec 18, 2023 | BUY |
Buy
+2.1% avg upside
34 analysts
|
$170.00
23.16% Upside
|
-1.5% | Β· |
|
BNTX
BioNTech SE
|
Oct 16, 2023 | HOLD |
Strong Buy
+37.0% avg upside
26 analysts
|
$111.00
13.02% Upside
|
+21.4% | Β· |
|
SE:SOBI
Swedish Orphan Biovitrum AB
|
Sep 01, 2023 | BUY |
Strong Buy
+2.4% avg upside
7 analysts
|
$260.00
41.02% Downside
|
+46.3% | Β· |
|
GB:CTEC
ConvaTec
|
Mar 22, 2023 | SELL |
Strong Buy
+38.0% avg upside
18 analysts
|
$200.00
7.76% Downside
|
-29.4% | Β· |
|
DE:FME
Fresenius Medical Care AG & Co. KGaA
|
Mar 07, 2023 | SELL |
Hold
+26.1% avg upside
24 analysts
|
$33.00
16.61% Downside
|
-5.4% | Β· |
|
GB:DCC
DCC plc
|
Dec 09, 2022 | BUY |
Buy
-1.9% avg upside
11 analysts
|
$6565.00
2.20% Upside
|
+28.5% | Β· |
|
GB:BNZL
Bunzl plc
|
Oct 20, 2022 | HOLD |
Hold
+3.9% avg upside
17 analysts
|
$2880.00
10.29% Upside
|
+6.9% | Β· |
|
CH:SGSN
SGS SA
|
Apr 08, 2022 | HOLD |
Buy
+1088.6% avg upside
26 analysts
|
$2860.00
2900.51% Upside
|
-15.6% | Β· |
|
FR:ERF
Eurofins Scientific
|
Apr 08, 2022 | HOLD |
Buy
+32.7% avg upside
17 analysts
|
$92.00
22.59% Upside
|
-36.7% | Β· |
|
FR:BVI
Bureau Veritas
|
Apr 08, 2022 | BUY |
Strong Buy
+10.3% avg upside
25 analysts
|
$31.00
15.49% Upside
|
+6.5% | Β· |
|
GB:ITRK
Intertek
|
Apr 08, 2022 | HOLD |
Buy
+786.6% avg upside
23 analysts
|
$5700.00
2.82% Downside
|
-22.0% | Β· |
|
GB:INF
Informa
|
Jan 26, 2022 | BUY |
Strong Buy
+492.3% avg upside
21 analysts
|
$685.00
21.18% Downside
|
+22.8% | Β· |
|
NL:IMCD
IMCD N.V.
|
Sep 28, 2021 | BUY |
Strong Buy
+35.0% avg upside
17 analysts
|
$195.00
101.82% Upside
|
-27.2% | Β· |
|
DE:BNR
Brenntag AG
|
Sep 28, 2021 | BUY |
Hold
+13.4% avg upside
27 analysts
|
$96.00
62.21% Upside
|
-22.4% | Β· |
|
GB:EXPN
Experian
|
Mar 19, 2021 | BUY |
Strong Buy
+289.0% avg upside
20 analysts
|
$3200.00
29.88% Upside
|
+26.7% | Β· |
|
GB:RS1
RS Group PLC
|
Jan 13, 2021 | BUY |
Strong Buy
-1.7% avg upside
10 analysts
|
$1000.00
28.11% Upside
|
+24.2% | Β· |
|
EXPGY
Experian
|
May 06, 2020 | BUY |
Buy
+13.3% avg upside
8 analysts
|
β | +27.8% | Β· |
|
GB:DPLM
Diploma
|
Apr 06, 2020 | HOLD |
Strong Buy
-26.4% avg upside
8 analysts
|
$1370.00
82.26% Downside
|
+83.3% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.